Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors.  The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s disease.   Sareum’s previously announced preclinical work identified three […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!